Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q2 2023 Earnings Presentation
19 slides from Mindwalk's earnings presentation, Dec 15, 2022
Slide 1: Fiscal 2023 Q2 Earnings Call
Fiscal 2023 Q2 Earnings Call December 15, 2022 ipatherapeutics.com NASDAQ: IPA
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal 2023 Q2 Business Update
Fiscal 2023 Q2 Business Update
Slide 4: YTD % Change Share Price, IPA vs Peers
FISCAL YEAR 2023 Q2 EARNINGS CALL YTD % Change Share Price, IPA vs Peers ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONFIDENTIAL 4
Slide 5: Newest Commercial Services, BioStrand
FISCAL YEAR 2023 Q2 EARNINGS CALL Newest Commercial Services, BioStrand Fee-for-Service Offerings • In silico immunogenicity analysis • Epitope mapping LENSai™ In silico, • Off-target analysis In parallel, • NLP-driven target analysis In an instant Early Adopter Services – Milestone Driven • Epitope
Slide 6: Organoids Market Size, 2021 to 2030 (USD Billion)
FISCAL YEAR 2023 Q2 EARNINGS CALL Organoids Market Size, 2021 to 2030 (USD Billion) ENSai™ In silico, In parallel, In an instant 6 ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONFIDENTIAL 6
Slide 7: Talem Updates
IMMUNOPRECISE ANTIBODIES c ae ‘ee Aalem Update
Slide 8: TATX-03 PolyTope®
FISCAL YEAR 2023 Q2 EARNINGS CALL TATX-03 PolyTope® Application(s)/ Latest milestone Value proposition/ Next steps/ problem to be reached differentiator(s) commercialization plan solved SARS-CoV-2 • Start-up Agreement • Superior to authorized • Expecting Phase 1/2a therapeutic with completed with th
Slide 9: PolyTope®
PolyTope® Regulatory In vitro In vivo CMC submission Expected Completion: Expected Completion: Q4 2022 Q1 2023 COMPLETED COMPLETED COMPLETED COMPLETED ✓ Pseudovirus neutralization ✓ Pharmacokinetics (PK) ✓ Research and Master Cell ✓ PIND application FDA screening variants ✓ Maximum tolerated dose Ba
Slide 10: TATX-112 & TATX-24: TrkB T-cell engagers
FISCAL YEAR 2023 Q2 EARNINGS CALL TATX-112 & TATX-24: TrkB T-cell engagers Application(s)/ Next steps/ Latest milestone Value proposition/ problem to be commercialization reached differentiator(s) solved plan Solid tumors such as • Bispecifics-demonstrated • Potential first-in-class antibody • In vi
Slide 11: Accelerator Building
FISCAL YEAR 2023 Q2 EARNINGS CALL Accelerator Building Utrecht, The Netherlands • 2x lab space • Expanded protein production capacity and capabilities
Slide 12: Fiscal 2023 Q2 Financial Update
Fiscal 2023 Q2 Financial Update
Slide 13: Trends in Revenue and Gross Profit
FISCAL YEAR 2023 Q2 EARNINGS CALL Trends in Revenue and Gross Profit Q2 Revenue Q2 Gross Profit $5,184 $4,755 $4,722 $2,789 $2,779 $2,575 Three Months Ended Three Months Ended Three Months Ended October 31, 2020 October 31, 2021 October 31, 2022 ©2022 ImmunoPrecise Antibodies Ltd. All rights reserve
Slide 14: Changes in Operating Expenses
FISCAL YEAR 2023 Q2 EARNINGS CALL Changes in Operating Expenses ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONFIDENTIAL 14
Slide 15: Changes in Other Income (Expense)
FISCAL YEAR 2023 Q2 EARNINGS CALL Changes in Other Income (Expense) ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONFIDENTIAL 15
Slide 16: Changes in Net Loss
FISCAL YEAR 2023 Q2 EARNINGS CALL Changes in Net Loss ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONFIDENTIAL 16
Slide 17: Changes in Cash Balance
FISCAL YEAR 2023 Q2 EARNINGS CALL Changes in Cash Balance October 31, 2022 $15,059 April 30, 2022 $29,965 $42 $408 ($1,297) ($14,055) Cash used in Cash used in Net Cash Effect of FX Operating Activities Investing Activities from Financing ©2022 ImmunoPrecise Antibodies Ltd. All rights reserved. CONF
Slide 18: Fiscal 2023 Q2 Earnings Call
Fiscal 2023 Q2 Earnings Call December 15, 2022 ipatherapeutics.com NASDAQ: IPA
Slide 19: Thank you
Thank you • Thank You Engineered for the race and the shared pursuit of clinical success www.ipatherapeutics.com NASDAQ: IPA
ImmunoPrecise Antibodies — Q2 2023 Earnings Presentation on 6ix